Anika Therapeutics | ANIK - Pre Tax Profit


Anika Therapeutics reported $764K in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Abbott USD 2.39B 27M Mar/2026
Agenus USD -10.61M 263.52M Dec/2025
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -162.1M 164.84M Mar/2026
Integra LifeSciences USD -2.41M 6.72M Mar/2026
Intrexon USD -60.48M 27.09M Jun/2024
J&J USD 7.82B 2.86B Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Ligand Pharmaceuticals USD 56.78M 84.36M Dec/2025
MacroGenics USD -36.77M 21.84M Mar/2026
Merit Medical Systems USD 51.06M 22.12M Dec/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 5.5B Dec/2025
Smith & Nephew USD 469M 70M Dec/2025
Stryker USD 1.7B 676M Dec/2025
Veracyte USD 29.97M 10.66M Mar/2026
Xencor USD -128.64M 124.37M Mar/2026
Zimmer Biomet Holdings USD 98M 320.7M Dec/2025